Study of Tecovirimat for Human Monkeypox Virus (STOMP)

项目总结 艾滋病临床试验小组(ACTG)一直站在推动艾滋病毒的临床研究的前沿 治疗和改善25年来艾滋病毒/艾滋病患者的健康。严谨的科学研究 ACTG开展的这项工作为目前的艾滋病毒治疗指南奠定了基础。在此应用程序中， ACTG网络实验室中心的竞争性更新，我们提出了一个改革性的实验室 研究议程利用了一个由著名临床和实验室研究人员组成的国际联盟 与世界一流的统计和数据管理中心合作开展尖端实验室 支持创新介入临床的研究、测试、分析开发和实验室培训 审判。ACTG网络实验室中心将提高科学知识和技术水平 通过在NIH/DAIDS的四个优先战略领域提供最先进的实验室支持来提高能力 治愈艾滋病毒；改进结核病的诊断和治疗；确定治愈传染性病毒的策略 肝炎；改进与艾滋病毒感染相关的非传染性并存的治疗和预防 并评估针对艾滋病毒感染的新干预措施。此外，实验室中心将提供 为艾滋病毒/艾滋病和病毒介导性癌症的口腔表现的治疗研究提供实验室支持。这个 在国内和国际现场继续扩大有效的、有质量保证的实验室计划 协议安全措施，最新的病毒学和分枝杆菌学分子分析；免疫学 和生物标记物；药理学；基因组学；以及与艾滋病毒-1感染相关的口腔病原体，将提供 推动亚洲及太平洋区域协调小组网络科学议程的基本框架。实验室中心将 继续监督ACTG网络已建立的标本和人类DNA储存库， 与其他网络协调特定的实验室测试和标准化操作程序 可行并继续支持国内技术人员和调查人员的实验室培训，以及 在国际上。

PROJECT SUMMARY The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of patients living with HIV/AIDS for 25 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG Network Laboratory Center, we propose a transformative laboratory research agenda that draws on an international consortium of prominent clinical and laboratory investigators in collaboration with a world-class Statistical and Data Management Center to conduct leading edge laboratory research, testing, assay development and laboratory training for the support of innovative interventional clinical trials. The component ACTG Network Laboratory Center will improve scientific knowledge and technical capability by providing state-of-the-art laboratory support in the four NIH/DAIDS priority areas of strategies to cure HIV; improve the diagnosis and treatment of tuberculosis; identify strategies to cure infectious viral hepatitis; improve the treatment and prevention of non-infectious co-morbidities associated with HIV infection and evaluate novel interventions targeting HIV infection. In addition, the Laboratory Center will provide laboratory support for therapeutic studies of oral manifestations of HIV/AIDS and virally mediated cancers. The continued expansion of an effective, quality-assured laboratory program at domestic and international sites for protocol safety measures, state-of-the-art molecular assays for virology and mycobacteriology; immunology and biomarkers; pharmacology; genomics; and oral pathogens associated with HIV-1 infection, will provide the essential framework for advancing the scientific agenda of the ACTG Network. The Laboratory Center will continue to provide oversight of established specimen and human DNA repositories for the ACTG Network, harmonize specific laboratory testing and standardized operating procedures with other Networks where feasible and continue to support the laboratory training of technologists and investigators domestically and internationally.